Search results for "Interleukin 1 Receptor Antagonist Protein"

showing 10 items of 19 documents

Genetic variation of the interleukin-1 family and nongenetic factors determining the interleukin-1 receptor antagonist phenotypes.

2009

The natural anti-inflammatory protein interleukin-1 receptor antagonist (IL-1Ra) inhibits the activity of IL-1 and is associated with vascular injury and metabolic disorders. We analyzed genetic and nongenetic determinants of the IL-1Ra phenotype. Fifteen haplotype-tagging single nucleotide polymorphisms (SNPs) in the IL-1α (IL1A), IL-1β (IL1B), and IL-1 receptor antagonist (IL-1RN) genes were determined in the Health 2000 survey (n = 6771) and European myocardial infarction (MI) survivors (n = 972). Three SNPs were genotyped in the FINRISK97 (FR97) study (n = 7222). We found 3 IL1RN variants that were associated with the IL-1Ra phenotype in the study populations and remained significant af…

AdultMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismMyocardial InfarctionSingle-nucleotide polymorphism030204 cardiovascular system & hematologyBiologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineEndocrinologyGene FrequencyMeta-Analysis as TopicInternal medicineGenetic variationmedicineHumansLongitudinal StudiesSurvivorsAllele frequency030304 developmental biologyAged2. Zero hungerGenetics0303 health sciencesGenetic VariationMiddle AgedExplained variation3. Good healthMinor allele frequencyInterleukin 1 Receptor Antagonist ProteinInterleukin 1 receptor antagonistEndocrinologyPhenotypeIL1AMultigene FamilyFemaleBody mass indexInterleukin-1Metabolism: clinical and experimental
researchProduct

Gonadotropin-releasing hormone (GnRH)-I regulation of interleukin (IL)-1b and IL-1 receptor antagonist expression in cultured human endometrial strom…

2008

Aim:  Human endometrium is an active site of cytokine production and action. Among these cytokines, the interleukin-1 (IL-1) system seems to be relevant to the embryonic implantation process. We have previously reported the production of GnRH-I by human blastocyst, as well as the presence of GnRH-I receptor in human endometrium. This suggests a close interaction between the immune and endocrine systems through these cytokine mediators in embryonic implantation. Methods:  To test the relevance of this interaction during embryonic implantation, we investigated GnRH-I regulation of IL-1b and IL-1ra mRNA and protein expression in human endometrial stromal cells using quantitative competitive po…

Adultendocrine systemmedicine.medical_specialtyStromal cellmedicine.drug_classmedicine.medical_treatmentInterleukin-1betaGonadotropin-releasing hormoneBiologyEndometriumGonadotropin-Releasing HormoneEndometriumInternal medicinemedicineHumansEmbryo ImplantationRNA MessengerBlastocystProtein PrecursorsReceptorObstetrics and GynecologyInterleukinReceptor antagonistInterleukin 1 Receptor Antagonist ProteinEndocrinologymedicine.anatomical_structureCytokineFemaleStromal Cellshormones hormone substitutes and hormone antagonistsJournal of Obstetrics and Gynaecology Research
researchProduct

The CO-releasing molecule CORM-2 is a novel regulator of the inflammatory process in osteoarthritic chondrocytes

2008

Previous work has shown that the CO-releasing molecule CORM-2 protects against cartilage degradation. The aim of this study was to examine whether CORM-2 can control the production of inflammatory mediators in osteoarthritic chondrocytes and determine the mechanisms involved.Primary cultures of chondrocytes from OA patients were stimulated with IL-1beta. The production of reactive oxygen species, nitrite, PGE(2), TNF-alpha and IL-1 receptor antagonist (IL-1Ra) were measured in the presence or absence of CORM-2. The expression of nitric oxide synthase-2 (NOS-2), cyclo-oxygenase-2 (COX-2) and microsomal PG E synthase-1 (mPGES-1) was followed by western blot and real-time PCR. Activation of nu…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentInterleukin-1betaNitric Oxide Synthase Type IINitric Oxidemedicine.disease_causeDinoprostoneChondrocyteNitric oxidechemistry.chemical_compoundChondrocytesRheumatologyWestern blotInternal medicineOsteoarthritisOrganometallic CompoundsmedicineHumansPharmacology (medical)Cells CulturedAgedProstaglandin-E SynthasesAged 80 and overchemistry.chemical_classificationReactive oxygen speciesDose-Response Relationship Drugmedicine.diagnostic_testTumor Necrosis Factor-alphabusiness.industryNF-kappa BHypoxia-Inducible Factor 1 alpha SubunitReceptor antagonistMolecular biologyIntramolecular OxidoreductasesInterleukin 1 Receptor Antagonist ProteinEndocrinologymedicine.anatomical_structureCytokinechemistryCyclooxygenase 2PhosphorylationFemaleReactive Oxygen SpeciesbusinessOxidative stressRheumatology
researchProduct

Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in…

2021

Abstract Background There is mounting evidence on the existence of a Pediatric Inflammatory Multisystem Syndrome-temporally associated to SARS-CoV-2 infection (PIMS-TS), sharing similarities with Kawasaki Disease (KD). The main outcome of the study were to better characterize the clinical features and the treatment response of PIMS-TS and to explore its relationship with KD determining whether KD and PIMS are two distinct entities. Methods The Rheumatology Study Group of the Italian Pediatric Society launched a survey to enroll patients diagnosed with KD (Kawasaki Disease Group – KDG) or KD-like (Kawacovid Group - KCG) disease between February 1st 2020, and May 31st 2020. Demographic, clini…

Coronary artery abnormalities; Hypotension; Kawasaki disease; Multisystem inflammatory syndrome associated with coronavirus disease; Myocarditis; Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; COVID-19; Child; Child Preschool; Coronary Artery Disease; Cough; Diarrhea; Dyspnea; Female; Glucocorticoids; Heart Failure; Humans; Hyperferritinemia; Hypotension; Immunoglobulins Intravenous; Immunologic Factors; Infant; Intensive Care Units Pediatric; Interleukin 1 Receptor Antagonist Protein; Italy; Lymphopenia; Male; Mucocutaneous Lymph Node Syndrome; Myocarditis; Platelet Aggregation Inhibitors; SARS-CoV-2; Shock; Systemic Inflammatory Response Syndrome; Tachypnea; Troponin T; VomitingMalelcsh:Diseases of the musculoskeletal systemcoronary artery abnormalities; hypotension; kawasaki disease; multisystem inflammatory syndrome associated with coronavirus disease; myocarditis; pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection; SARS-CoV-2; age distribution; antirheumatic agents; aspirin; C-reactive protein; COVID-19; child ; preschool; coronary artery disease; cough; diarrhea; yspnea; female; glucocorticoids; heart failure; humans; hyperferritinemia; hypotension; immunoglobulins; intravenous; immunologic factors; infant; intensive care units; pediatric; interleukin 1 receptor antagonist protein; italy; lymphopenia; male; mucocutaneous lymph node syndrome; myocarditis; platelet aggregation inhibitors; SARS-CoV-2; shock; systemic inflammatory response syndrome; tachypnea; troponin T; vomitingMyocarditiCoronary Artery Disease030204 cardiovascular system & hematologySARS-CoV-2 Kawasaki disease Pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection Myocarditis Hypotension Multisystem inflammatory syndrome associated with coronavirus disease Coronary artery abnormalitiesCoronary artery diseaseSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineGlucocorticoidImmunologic FactorMultisystem inflammatory syndrome associated with coronavirus diseaseImmunology and AllergyChildCoronary artery abnormalitieFisher's exact testPediatricTachypneabiologylcsh:RJ1-570Antirheumatic AgentImmunoglobulins IntravenousShockPediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infectionSettore MED/38Systemic Inflammatory Response SyndromeIntensive Care UnitsMyocarditisC-Reactive ProteinItalyAntirheumatic AgentsChild PreschoolCohortsymbolsPlatelet aggregation inhibitorFemaleHypotensionIntravenousCoronary artery abnormalitiesHumanResearch ArticleDiarrheamedicine.medical_specialtyMyocarditisVomitingImmunoglobulinsMucocutaneous Lymph Node SyndromeIntensive Care Units Pediatric03 medical and health sciencessymbols.namesakeAge DistributionRheumatologyTroponin TInternal medicineLymphopeniamedicineHumansImmunologic FactorsPreschoolGlucocorticoids030203 arthritis & rheumatologyHeart FailureAspirinKawasaki diseasebusiness.industrySARS-CoV-2Platelet Aggregation InhibitorC-reactive proteinCOVID-19Infantlcsh:Pediatricsmedicine.diseaseSystemic inflammatory response syndromeInterleukin 1 Receptor Antagonist ProteinDyspneaCoughImmunoglobulins IntravenouPediatrics Perinatology and Child Healthbiology.proteinKawasaki diseaseHyperferritinemialcsh:RC925-935businessPlatelet Aggregation InhibitorsPediatric rheumatology online journal
researchProduct

The prognostic value of four interleukin-1 gene polymorphisms in caucasian women with breast cancer – a multicenter study

2009

Abstract Background The proinflammatory cytokine interleukin-1 (IL-1) is known to play an important role in the carcinogenesis of breast cancer. Although IL-1 gene polymorphisms were reported to be associated with increased risk of breast cancer, their influence on survival of Caucasian breast cancer patients remains to be shown. Methods We studied the influence of four common gene polymorphisms (IL1A -889C/T, IL1B -511C/T, IL1B +3953E1/E2, and IL1RN long/2) of the IL-1 family on survival in 262 Caucasian patients with breast cancer by univariate and multivariate survival analysis. The combined effect of the four gene polymorphisms on overall survival was studied by haplotype analysis. Resu…

Oncologymedicine.medical_specialtyCancer ResearchBreast Neoplasmsmedicine.disease_causelcsh:RC254-282Disease-Free SurvivalWhite PeopleBreast cancerInternal medicineGeneticsMedicineHumansAlleleAllelesPolymorphism Geneticbusiness.industryHaplotypeCancerOdds ratioMiddle Agedmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensInterleukin 1 Receptor Antagonist ProteinIL1AOncologyImmunologyFemaleGene polymorphismbusinessCarcinogenesisInterleukin-1Research ArticleBMC Cancer
researchProduct

Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases.

2021

Abstract The interleukin (IL)-1 family member IL-1α is a ubiquitous and pivotal pro-inflammatory cytokine. The IL-1α precursor is constitutively present in nearly all cell types in health, but is released upon necrotic cell death as a bioactive mediator. IL-1α is also expressed by infiltrating myeloid cells within injured tissues. The cytokine binds the IL-1 receptor 1 (IL-1R1), as does IL-1β, and induces the same pro-inflammatory effects. Being a bioactive precursor released upon tissue damage and necrotic cell death, IL-1α is central to the pathogenesis of numerous conditions characterized by organ or tissue inflammation. These include conditions affecting the lung and respiratory tract, …

0301 basic medicineMyocarditisil-1βmedicine.medical_treatmentAutoimmunity Cancer Cytokines IL-1 IL-1αIL-1β Inflammation Interleukin 1 Receptor Antagonist Protein Receptors Interleukin-1 SARS-CoV-2 COVID-19 Interleukin-1alpha Humansil-1αImmunologyreceptorsInflammationmedicine.disease_causeAutoimmunityPathogenesis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticail-1Interleukin-1alphamedicinecancerImmunology and AllergyHumans030203 arthritis & rheumatologyAnakinrabusiness.industrySARS-CoV-2autoimmunityInterleukinCOVID-19Receptors Interleukin-1medicine.diseasecytokinesRilonaceptInterleukin 1 Receptor Antagonist Protein030104 developmental biologyCytokineinflammationImmunologyautoimmunity; cancer; cytokines; il-1; il-1α; il-1β; inflammation; humans; interleukin 1 receptor antagonist protein; receptors interleukin-1; SARS-COV-2; COVID-19; interleukin-1alphamedicine.symptombusinessinterleukin-1medicine.drugAutoimmunity reviews
researchProduct

A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis

2003

Abstract Objective . The interleukin-1 (IL-1) family, that is, IL-1α and β and the IL-1 receptor antagonist (IL-1RA), is known to modulate various tumorgenic and tumorcidal effects in humans. Its biological function in squamous cell carcinogenesis of various anatomical sites has been stressed. Although various studies showed a certain association between genes encoding the IL-1 family and human malignancies, no data with respect to vulvar cancer have been published to date. Methods . We ascertained four polymorphisms of the IL-1α gene ( IL1A C[−889]T), the IL-1β gene ( IL1B promoter C[-511]T and IL1B exon 5 position +3953), and the IL-1RA gene ( IL1RN intron 2) in 68 patients with surgicall…

AdultSialoglycoproteinsBiologyBioinformaticsmedicine.disease_causePolymerase Chain ReactionExonGene clustermedicineHumansPromoter Regions GeneticAllelesAgedNeoplasm StagingAged 80 and overVulvar neoplasmPolymorphism GeneticVulvar NeoplasmsObstetrics and GynecologyInterleukinExonsMiddle AgedVulvar cancermedicine.diseaseInterleukin 1 Receptor Antagonist ProteinCell Transformation NeoplasticInterleukin 1 receptor antagonistOncologyIL1AMultigene FamilyCarcinoma Squamous CellCancer researchFemaleCarcinogenesisInterleukin-1Gynecologic Oncology
researchProduct

Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: A decision tree for clini…

2009

Objective To survey rheumatologists' preferences for the choice of a second-line disease-modifying antirheumatic drug (DMARD) after inadequate response with methotrexate (MTX) therapy in rheumatoid arthritis (RA). Methods Thirty-six rheumatologists stated their preferences for RA treatment after inadequate response with MTX therapy (optimal dose at least 6 months). From the initial scenario, we derived 54 vignettes varying by rheumatoid factor or anti–cyclic citrullinated peptide antibody presence, swollen joint count, Disease Activity Score in 28 joints, and structural damage. Respondents stated their preference among 5 therapeutic options: MTX continuation, switch to another conventional …

MESH: Antirheumatic AgentsMESH: Decision TreesMESH: Treatment FailureArthritisMESH: Antibodies Anti-IdiotypicMESH: Logistic ModelsLogistic regressionSeverity of Illness IndexArthritis Rheumatoid0302 clinical medicineimmune system diseasesImmunology and AllergyMESH: Data CollectionPharmacology (medical)Treatment Failure030212 general & internal medicinePractice Patterns Physicians'skin and connective tissue diseasesMESH: Arthritis RheumatoidData CollectionAntibodies Anti-Idiotypic3. Good healthMESH: Interleukin 1 Receptor Antagonist ProteinMESH: Methotrexate[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemAntirheumatic AgentsRheumatoid arthritismedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyMESH: Rheumatoid FactorImmunologyPeptides Cyclic03 medical and health sciencesRheumatologyRheumatoid FactorMESH: Severity of Illness IndexInternal medicineSeverity of illnessmedicineHumansRheumatoid factorMESH: Physician's Practice PatternsMESH: Peptides Cyclic030203 arthritis & rheumatologyAnakinraMESH: HumansTumor Necrosis Factor-alphabusiness.industryDecision Treesmedicine.diseaseRheumatologyInterleukin 1 Receptor Antagonist ProteinLogistic ModelsMethotrexateMESH: Tumor Necrosis Factor-alphaPhysical therapyMethotrexatebusinessArthritis & Rheumatism
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Differential role of interleukin-1β in neuroinflammation-induced impairment of spatial and nonspatial memory in hyperammonemic rats.

2019

Activated microglia and increased brain IL-1β play a main role in cognitive impairment in much pathology. We studied the role of IL-1β in neuroinflammation-induced impairment of the following different types of learning and memory: novel object recognition (NOR), novel object location (NOL), spatial learning, reference memory (RM), and working memory (WM). All these processes are impaired in hyperammonemic rats. We assessed which of these types of learning and memory are restored by blocking the IL-1 receptor in vivo in hyperammonemic rats and the possible mechanisms involved. Blocking the IL-1 receptor reversed microglial activation in the hippocampus, perirhinal cortex, and prefrontal cor…

0301 basic medicineMaleInterleukin-1betaPostrhinal cortexHippocampusBiochemistryHippocampusReceptors N-Methyl-D-Aspartate03 medical and health sciences0302 clinical medicineReceptors GABAAmmoniaMemoryPerirhinal cortexGeneticsmedicineMemory impairmentAnimalsHyperammonemiaReceptors AMPARats WistarPrefrontal cortexMolecular BiologyNeuroinflammationCerebral CortexInflammationMicrogliabusiness.industryWorking memoryAnimal FeedRatsInterleukin 1 Receptor Antagonist ProteinProtein Subunits030104 developmental biologymedicine.anatomical_structureGene Expression RegulationReceptors GlutamateMicrogliabusinessNeuroscience030217 neurology & neurosurgeryBiotechnologyFASEB journal : official publication of the Federation of American Societies for Experimental Biology
researchProduct